Some healthcare insurance plans may provide coverage when semaglutide is used to treat type 2 diabetes, while coverage for weight-loss purposes may be more restricted
Finally, TRANSCEND-T2D-3 (NCT06297603) will compare retatrutide to placebo over 14 months, in people with inadequately controlled T2D and moderate-or-severe renal impairment on basal insulin
Its also designed to monitor patients for safety and success, which is something lacking in mail-order injectables for weight loss or go-it-alone workouts and diets
Furthermore, confounding factors such as the motivation to start taking the medication in the first place could affect these results and were not controlled for
The manufacturer ran clinical pharmacology studies to test that concern against real drugs
The platform is young, and the clinical infrastructure (CareGLP, named pharmacy partners, and LegitScript certification) checks out